Biosimilars in Cancer Therapy and Beyond: Implications for Nursing Practice
Recorded On: 06/17/2020
Commerical Support: Coherus
Biosimilars are biologics, such as hormones and monoclonal antibodies, which are produced from living systems that may be sourced from nature or “genetically engineered,” AKA “biotech” products. A biosimilar is defined as a biologic product that is highly similar to and has no clinically meaningful differences from an existing FDA-approved reference biologic. Biologics have revolutionized the treatment and management of many malignant diseases, such as cancer. Biosimilars provide opportunities for improving healthcare access and outcomes, as well as reducing overall healthcare costs because of their cheaper price, relative to their reference biologics.
This webinar will guide the participant through the brief history of biologics. We will explore the science and the advances that have been made since the first EMA-approved biosimilar, omnitropin, a recombinant human growth hormone with indications for pituitary dwarfism, Prader-Willi Syndrome, and Turner Syndrome, hit the EU market in 2006, as well as the first FDA-approved biosimilar, filgrastim-sndz hit the US market in 2015. A robust discussion on the progress of biosimilars in Europe and the US, relating to research and development, access, outcomes, cost savings, and nursing implications before, during, and after biosimilar administration are included in this webinar.
Learning Outcomes: At the conclusion of this webinar, learners will be able to:
o Describe the history, science and advances in biosimilar development, analytical methods, and commercialization
o Verbalize the step-wise approach for the development of biosimilars
o Outline the nursing implications for interchangeability and substitution issues concerning biosimilars
o Summarize the FDA-approved indications of biosimilars and the nursing roles before, during, and after their administrations
Joseph D. Tariman, PhD, RN, ANP-BC, FAAN
Dr. Joseph D. Tariman, PhD, RN, ANP-BC, FAAN, is the editor and author of the only myeloma nursing textbooks (1st, 2nd, and the upcoming 3rd editions), author of eight myeloma book chapters, 18 conference abstracts, and 72 PubMed-indexed, peer-reviewed papers. He has given hundreds of presentations on topics affecting myeloma nursing practice, including the use of biosimilars, at local, regional, national and international conferences. He is currently an associate editor for the Clinical Journal of Oncology Nursing through June 2020.
CRNI® RUs: This session has been approved for 1 CRNI® recertification unit and meets the non INS Meeting criteria.
Contact Hours: This session has been approved for 1 contact hour
Expiration date for receipt of contact hours: June 17, 2023
To receive contact hours for this educational activity, you are required to attend the entire educational activity and complete the evaluation.
INS is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.